|
 |
VinorelbineThis page contains recent news articles, when available, and an overview of Vinorelbine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Vinorelbine (when available) Vinorelbine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vinorelbine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. For the treatment of non-small-cell lung carcinoma Mechanism Of Action: The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. News Articles on Vinorelbine ADVENTRX æ??交ANX-530æ–°è?¯ä¸Šå¸‚申请 - 06 Jan 2010 ADVENTRX PharmaceuticaLS (ANX)宣布，å?‘美国FDAæ??交ANX-530 (vinorelbine注射用乳剂)æ–°è?¯ä¸Šå¸‚申请。 å…?è´£å£°æ˜Žï¼šæœ¬æ–‡ä»…ä»£è¡¨ä½œè€…ä¸ªäººè§‚ç‚¹ï¼Œä¸Žå‡¤å‡°ç½‘æ— å…³ã€‚ ... 凤凰网 Adventrx Asks FDA to Approve Its Formulation of Anti-Cancer Drug - Jan 4, 2010 Adventrx says ANX-530 is its proprietary emulsion formulation of vinorelbine chemotherapy that is intended to reduce the incidence and severity of vein ... Xconomy Adventrx Pharmaceuticals Inc. (AMEX: ANX) still running strong. Gains nearly ... - Dec 28, 2009 They recently announced that they intend to submit an NDA for ANX-530 (vinorelbine emulsion) by the end of 2009, having successfully completed the final ... Small Cap Network ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application - Jan 4, 2010 The Company is seeking approval of ANX-530 for the same indications as Navelbine®, a branded formulation of vinorelbine, including non-small cell lung ... CNNMoney.com (press release) Adventrx Inching Closer To NDA Filing Of Emulsion Formulation Of Chemotherapy Drug - Dec 20, 2009 Navelbine, a branded formulation of vinorelbine, is approved in the US to treat advanced non-small cell lung cancer as a single agent or in combination with ... RTT News Market Report -- In Play () - Jan 4, 2010 ...submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion). ... MSN Money Neratinib Shows Promise in Treatment of HER2-positive Breast Cancer - Dec 18, 2009 At SABCS 2009 the results of an ongoing Phase I/II clinical trial of neratinib in combination with Navelbine® (vinorelbine) in women with HER2-positive ... Cancer Consultants Adding Bevacizumab to Second-Line Chemo Improves Progression-Free Survival in ... - Dec 12, 2009 The effect of adding bevacizumab to either paclitaxel plus docetaxel, gemcitabine or vinorelbine, as chosen by the investigator, was assessed and compared ... DG News Adjuvant chemotherapy improves survival in early NSCLC - Dec 16, 2009 NEW YORK (Reuters Health) - Treatment of early-stage non-small-cell lung cancer (NSCLC) with cisplatin and vinorelbine after complete tumor resection ... Curetoday.com (press release) Gold & Dollar Redux, Looks at TRLG, MNKD, BBI, MNTA, ANX, & NEWP - Dec 24, 2009 The new drug turns the chemotherapy drug vinorelbine tartrate - or Navelbine - into an emulsion intended to treat non-small cell lung cancer. ... Small Cap Network Ichan's Adventrx Pharmaceuticals Ready To Run - Dec 23, 2009 ...which is a novel emulsion formulation of GlaxoSmithKline's (NYSE: GSK) chemotherapy drug Navelbine (also known as vinorelbine tartrate). ... FOXBusiness Avastin for breast cancer shines in PFS but not overall survival - Dec 15, 2009 ...(investigator's choice, including paclitaxel, docetaxel, gemcitabine, capecitabine and vinorelbine) plus Avastin or to chemotherapy plus placebo. ... Pharma Times ADENTRX set to move in on GlaxoSmithKline's lucrative oncology drug - Jan 4, 2010 ...the upside with ADVENTRX is still tremendous, especially since ANX already has a product on the launching pad: ANX 530 Vinorelbine (Navelbine) Emulsion. ... FOXBusiness Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival ... - Dec 11, 2009 Vinorelbine Alone (76 patients) Hazard Ratio 0.64 0.90 0.73 1.42 Overall Survival (not statistically significant at this interim analysis with 57% of ... FOXBusiness Ð?дювантната химиотерапиÑ? подброÑ?ва преживÑ?емоÑ?тта при ранен недребноклетъчен ... - Dec 16, 2009 Ð?дювантната химиотерапиÑ? Ñ? cisplatin и vinorelbine Ñ?лед пълна туморна резекциÑ? значително подобрÑ?ва 5-годишната преживÑ?емоÑ?Ñ‚ при пациенти Ñ? недребноклетъчен ... DoctorBG.com Where to buy colchicine online? top offers for colchicine, Alway - 14 Nov 2009 If you have any colchicine hot flashes about the extreme asthma of vinorelbine, find your doctor. The colchicine hot flashes may confusion from 1/2 ... iFun.de (Blog) Curse of the nocebo effect - Oct 31, 2009 Vinorelbine and gemcitabine are two good examples of the last class, ie those with very little potential to cause vomiting. Yet some patients tar all cancer ... Malaysia Star BUYINS.NET: ANSW, NEWS, ANX, WPTE, ZAP, PGTI Expected To Be Lower After ... - Nov 2, 2009 Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a ... TMC Net New Oral Agent, Tasquinimod, May Have Activity in Prostate Cancer - Oct 26, 2009 ...with HRPC include: Taxotere® (docetaxel), Emcyt® (estramustine), Novantrone® (mitoxantrone), ixabepilone, Navelbine® (vinorelbine), and satraplatin. ... Cancer Consultants More chemotherapy may not be better in NSCLC - Nov 3, 2009 Can continuing vinorelbine after platinum doublet be considered equal to docetaxel after platinum doublets? Are six or more courses of platinum doublets ... Oncology Update Med BioGene Announces Positive Results From Validation Study of LungExpress DXTM - Oct 19, 2009 ...in an adjuvant chemotherapy (cisplatin / vinorelbine) clinical trial showed that those patients classified by LungExpress Dx TM as high risk benefitted, ... PR-CANADA.net (press release) Vinorelbine plus trastuzumab combination as first-line therapy for... - Sep 12, 2006 Correspondence: Dr A Chan, Suite 41, 146 Mounts Bay Road, Perth 6000, Australia. E-mail: arlene.chan@bigpond.com. Received 25 May 2006; Revised 31 July 2006 ... Nature.com Adjuvant Vinorelbine and Cisplatin May Be Helpful in... - Jun 22, 2005 June 22, 2005 — Adjuvant chemotherapy with vinorelbine and cisplatin prolongs survival for patients with completely resected early stage non–small-cell lung ... Medscape vinorelbine tartrate - Jun 4, 2008 Vinorelbine interferes with the cell's ability to reproduce. Vinorelbine is an intravenous (IV) medication. The type and extent of a cancer determines the ... WebMD Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a... - Nov 23, 2006 Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non-small-cell lung cancer (NSCLC). ... Nature.com The feasibility of using topotecan, vinorelbine, thiotepa and... - Feb 28, 2008 The success of haematopoietic stem cell transplantation depends upon the pretransplant leukaemic burden. 1 In relapsed or refractory acute leukaemia and ... Nature.com Epirubicin–vinorelbine vs FEC100 for node-positive, early breast... - Dec 1, 2006 The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m -2 , epirubicin 100 mg m -2 and cyclophosphamide 500 ... Nature.com Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients... - Dec 9, 2008 Correspondence: Dr G Huebner, Hematology and Oncology, Sana Kliniken Ostholstein, Muhlenkamp 5, 23758 Oldenburg, Holstein, Germany. E-mail: lghuebner@web.de ... Nature.com Vinorelbine (Systemic). - Jul 28, 2005 Vinorelbine (vi-NOR-el-been ) belongs to the general group of medicines known as antineoplastics. It is used to treat some kinds of lung cancer. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Vinorelbine (Systemic).(Drug overview) - May 1, 2006 Vinorelbine (vi-NOR-el-been ) belongs to the general group of medicines known as antineoplastics. It is used to treat some kinds of lung cancer. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … GAINS RIGHTS TO ORAL VINORELBINE FROM PIERRE FABRE By … - Jul 26, 2005 Adding to its pipeline of cancer drugs, Novacea Inc. licensed exclusive North American rights to an oral version of vinorelbine sold in Europe by French ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Gemcitabine Enhances Vinorelbine in Metastatic Breast Cancer: … - Jun 6, 2006 By Paula Moyer. ATLANTA, GA -- June 6, 2006 -- Gemcitabine adds efficacy to vinorelbine without undue toxicity compared with vinorelbine alone in patients ... DG News Vinorelbine/Cisplatinum May Help Bladder Cancer Patients: Presented... - Feb 9, 2007 By Jill Stein. PARIS, FRANCE -- February 9, 2007 -- The combination of cisplatinum and vinorelbine has demonstrated a favorable response rate in patients ... DG News Cancer Therapy; Pemetrexed and vinorelbine used to treat patients... - Nov 8, 2005 2005 NOV 8 - (NewsRx.com) -- Pemetrexed and vinorelbine could be used as a first-line treatment of patients with non-small cell lung cancer (NSCLC). ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Chemotherapy Does Not Improve Survival in Patients With Mesothelioma - May 20, 2008 In this trial, ASC plus vinorelbine was statistically indistinguishable from ASC ... Those assigned to vinorelbine received 1 injection of vinorelbine every ... Medscape Hana will license three cancer drugs for $11.5M - Mar 17, 2006 Vincristine, vinorelbine and topotecan are all approved chemotherapy drugs. ... Trials for Marquibo and for vinorelbine will start this year, ... Bizjournals.com Capecitabine and vinorelbine in elderly patients (older than 65... - Jan 1, 2005 Synopsis: This regimen of capecitabine and vinorelbine is well tolerated and effective in elderly patients with metastatic breast cancer. ... Free with registration - Clinical Oncology Alert - AccessMyLibrary.com … Followed by Vinorelbine Appears as Effective as Vinorelbine Followe... - Feb 8, 2008 By Shazia Qureshi. PARIS, FRANCE -- February 8, 2008 -- Whether capecitabine treatment is given before vinorelbine treatment or vice versa does not appear ... DG News … to Treatment With Capecitabine and Vinorelbine: Presented at SABCS - Dec 18, 2006 ...[Presentation title: Capecitabine (C) and Vinorelbine (V) in Elderly Patients (pts.) With Metastatic Breast Cancer (MBC) as 1st Line Treatment: a ... DG News Cancer Therapy; Use of estramustine, vinorelbine, and mitoxantrone... - Nov 29, 2005 2005 NOV 29 - (NewsRx.com) -- The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer was deemed feasible. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones … Cleared To Initiate Vinorelbine Emulsion Bioequivalence Study - Dec 29, 2006 ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that its Investigational New Drug (IND) application for the clinical development of its ... Medical News Today - Medical News Today (press release) ADVENTRX Announces ANX-530 Safety Data From Registrational … - May 16, 2008 ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the US to ... Lifescience-online Cancer Drugs; RLIP76 transported vinorelbine and mediated drug … - Apr 4, 2005 2005 APR 4 - (NewsRx.com) -- RLIP76 transported the cancer drug, vinorelbine, and mediated drug resistance in non-small cell lung cancer. ... Pay-Per-View - AIDS Weekly - Factiva, from Dow Jones … Cleared to Initiate Vinorelbine Emulsion Bioequivalence Study. - Dec 26, 2006 SAN DIEGO, Dec. 26 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. today announced that its Investigational New Drug (IND) application for the ... Free with registration - PR Newswire - AccessMyLibrary.com Cancer Drugs; RLIP76 transported vinorelbine and mediated drug … - Apr 8, 2005 2005 APR 8 - (NewsRx.com) -- RLIP76 transported the cancer drug, vinorelbine, and mediated drug resistance in non-small cell lung cancer. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Chemotherapy Does Not Improve Treatment For Mesothelioma - May 15, 2008 Patients in the ASC/vinorelbine group also showed improved survival, ... However, exploratory analyses suggested that vinorelbine merits further ... Medical News Today - Medical News Today (press release) IASLC: Third-Generation Chemotherapeutics Improve Survival in Real- … - Sep 5, 2007 Vinorelbine was the only third-generation chemotherapy agent, ... The researchers also looked at survival according to use of vinorelbine across the country ... MedPage Today Results From ADVENTRX Vinorelbine Preclinical Studies Accepted for … - Jan 19, 2006 SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. today announced that data from preclinical studies of ANX-530 (vinorelbine ... Free with registration - PR Newswire - AccessMyLibrary.com Vinorelbine-Capecitabine VersusDocetaxel-Doxorubicin- … - Mar 13, 2008 Among patients without early response to treatment with two TAC cycles, similar efficacy was observed by switching to four NX cycles and by continuing with ... Medscape American Pharmaceutical Partners Receives Approval for Vinorelbine … - Apr 19, 2005 According to IMS, sales of vinorelbine tartrate were approximately $61 ... Vinorelbine Tartrate is indicated as a single agent or in combination with ... $4.95 - PR Newswire - ECNext Hana Biosciences to Present Data On Three Compounds At the AACR- … - Oct 9, 2007 Hana will present the first clinical data related to vinorelbine Optisomes ... Vinorelbine, a semi-synthetic vinca alkaloid, is a microtubule inhibitor that ... Nanotechnology News - Nanotechnology News (press release) Cisplatin and Vinorelbine Standard of Care in Lung Cancer - Oct 2, 2006 October 2, 2006 (Istanbul) — The combination of cisplatin with vinorelbine should be the standard of care for non–small-cell lung cancer (NSCLC) after ... Medscape Cancer Therapy; Vinorelbine and gemcitabine used as third-line … - Oct 4, 2005 We conducted a phase I study of a combination of vinorelbine and ... Cohorts of 3 to 7 patients received vinorelbine at doses ranging from 20 to 25 mg/m2, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Hana Biosciences Presents Alocrest and Menadione Data At the … - Jul 7, 2008 Alocrest is Hana's OPTISOME(tm) encapsulated formulation of vinorelbine ... Vinorelbine, a semi-synthetic vinca alkaloid, is a microtubule inhibitor that ... CNNMoney.com Adjuvant Docetaxel More Effective Than Vinorelbine for Early Breast … - Feb 22, 2006 NEW YORK FEB 22, 2006 (Reuters Health) - Docetaxel is more effective than vinorelbine when administered prior to fluorouracil, epirubicin and ... Cancerpage.com Can adjuvant chemotherapy improve survival in patients with early... - Aug 17, 2005 ...(2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell ... To assess whether adjuvant vinorelbine plus cisplatin improves survival in ... Nature.com Alocrest Demonstrates Antitumor Activity in Trial - Feb 13, 2008 The trial was designed to assess the safety, tolerability and preliminary efficacy of Alocrest (vinorelbine liposomes injection, Optisome). ... FDA news - FDA news (subscription) Cancer Drugs; Curcumin enhanced vinorelbine-mediated apoptosis in … - Jul 11, 2005 ..."Pre-treatment with Curcumin enhanced the Vinorelbine induced apoptosis to 61.3%. The findings suggest that Curcumin has the potential to act as an adjuvant ... Pay-Per-View - Cancer Vaccine Week - Factiva, from Dow Jones Hana Biosciences Completes Licensing of Three Targeted Cancer Drug … - May 8, 2006 ...--Sphingosome Encapsulated Vinorelbine Targeted to Start Clinical Trials in ... --Sphingosome encapsulated vinorelbine, for which a US Investigational New ... Free with registration - Business Wire - AccessMyLibrary.com Synthetic lethal screen identification of chemosensitizer loci in... - Apr 12, 2007 We next examined the consequence of target depletion on responses to a broad range of concentrations of paclitaxel, vinorelbine and gemcitabine. ... Nature.com Cancer Drugs; Curcumin enhanced vinorelbine-mediated apoptosis in … - Jul 11, 2005 ..."Pre-treatment with Curcumin enhanced the Vinorelbine induced apoptosis to 61.3%. The findings suggest that Curcumin has the potential to act as an adjuvant ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones … ; Brain metastases responded to vinorelbine combined with protracted... - Sep 12, 2006 Vinorelbine dose was 15 mg/m2 in 7 patients, 20 mg/m2 in 5, 25 mg/m2 in 4 and 30 mg/m2 in 6. Grades 3 and 4 neutropenia developed in 6 patients, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Cetuximab Plus Platinum-Based Therapy Sets New Standard for First- … - Jun 2, 2008 Median response rate was 36% in the cisplatin/vinorelbine/cetuximab group compared with 29% in the cisplatin/vinorelbine alone group (P = .012). ... DG News Data From XYOTAX(TM) Clinical Program Presented at the 11th World … - Jul 6, 2005 When compared to vinorelbine (32 patients) on the STELLAR 4 trial, XYOTAX patients demonstrated superior survival. In addition, in the first-line STELLAR 3 ... RedOrbit Prostate Cancer: Clinical Study Demonstrates Superior Efficacy Of … - May 24, 2007 However, other clinical trials indicated that the drug vinorelbine, which like docetaxel acts on cellular microtubuli, also produces impressive results and ... Medical News Today - Medical News Today (press release) … : Results From ADVENTRX Vinorelbine Preclinical Studies Accepted... - Jan 19, 2006 Results From ADVENTRX Vinorelbine Preclinical Studies Accepted for Presentation at AACR Annual Meeting. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Cancer Therapy; Vinorelbine showed no clinical influence on patients ... - Mar 29, 2005 2005 MAR 29 - (NewsRx.com) -- Despite a favorable toxicity profile, vinorelbine has shown no clinical activity in patients with metastatic melanoma. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones IGEV regimen and a fixed dose of lenograstim: an effective mobilizatio... - Oct 1, 2007 We explored the efficacy of the IGEV regimen (ifosfamide, gemcitabine, vinorelbine and prednisone) combined with a fixed dose of lenograstim (263 g/day) to ... Nature.com … Cleared to Initiate Vinorelbine Emulsion Bioequivalence Study. -... - Dec 26, 2006 ADVENTRX Cleared to Initiate Vinorelbine Emulsion Bioequivalence Study. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Cancer Therapy; Vinorelbine showed no clinical influence on patients ... - Apr 1, 2005 2005 APR 1 - (NewsRx.com) -- Despite a favorable toxicity profile, vinorelbine has shown no clinical activity in patients with metastatic melanoma. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones … ; Breast cancer treated by gemcitabine in combination with vinorelbi... - Apr 4, 2006 ..."The combination of gemcitabine (1000 mg/m2) and vinorelbine (25 mg/m2) was ... The combination of vinorelbine and gemcitabine is an active scheme in ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones … ; Treatment including gemcitabine and vinorelbine is proposed for... - Dec 20, 2005 2005 DEC 20 - (NewsRx.com) -- Induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with etoposide and cisplatin ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Cancer Therapy; Vinorelbine showed no clinical influence on patients ... - Mar 28, 2005 2005 MAR 28 - (NewsRx.com) -- Despite a favorable toxicity profile, vinorelbine has shown no clinical activity in patients with metastatic melanoma. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Breast Cancer; Vinorelbine, epirubicin, 5-FU combo is manageable... - Apr 19, 2005 2005 APR 19 - (NewsRx.com) -- Researchers in Italy report that continuous infusion with combined vinorelbine, epirubicin, and 5-fluorouracil is "an active ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Breast Cancer; Vinorelbine, epirubicin, 5-FU combo is manageable... - Apr 18, 2005 2005 APR 18 - (NewsRx.com) -- Researchers in Italy report that continuous infusion with combined vinorelbine, epirubicin, and 5-fluorouracil is "an active ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones vinorelbine Pierre Fabre, Novacea licensing termination. - Nov 13, 2006 Novacea reported on 1 November 2006 that it has returned the development and commercialization rights to oral vinorelbine in the USA and Canada to Pierre ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones XYOTAX(TM) Significantly Prolongs Survival in Poor Performance Status... - May 15, 2005 Vinorelbine is the only single agent approved in the United States for treating first-line lung cancer. On study deaths were also significantly reduced ... RedOrbit Breast Cancer; Cisplatinum and vinorelbine studied in phase II trial - Oct 11, 2005 2005 OCT 11 - (NewsRx.com) -- Researchers conducted a clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC). ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones … Partners Receives Approval for Vinorelbine Tartrate. - PR Newswire... - Apr 19, 2005 American Pharmaceutical Partners Receives Approval for Vinorelbine Tartrate. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research vinorelbine Pierre Fabre conducting phase II trial of oral formulation... - Sep 18, 2006 Vinorelbine iv (NAVELBINE) is marketed in many markets worldwide for ... vinorelbine, vinorelbine tartrate, PM 259, DC 1, KW 2307, BW 7Y89, KW 3407, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Cancer Therapy; Oblimersen and vinorelbine diminish malignant lung … - Feb 7, 2005 2005 FEB 7 - (NewsRx.com & NewsRx.net) -- Oblimersen and vinorelbine diminish malignant lung tumors in murine models. According to recent research published ... Pay-Per-View - Cancer Gene Therapy Week - Factiva, from Dow Jones Cancer Therapy; Oblimersen and vinorelbine diminish malignant lung … - Feb 10, 2005 2005 FEB 10 - (NewsRx.com & NewsRx.net) -- Oblimersen and vinorelbine diminish malignant lung tumors in murine models. ... Pay-Per-View - Gene Therapy Weekly - Factiva, from Dow Jones Cancer Therapy; Oblimersen and vinorelbine diminish malignant lung … - Feb 12, 2005 2005 FEB 12 - (NewsRx.com & NewsRx.net) -- Oblimersen and vinorelbine diminish malignant lung tumors in murine models. ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Novacea acquires rights to oral vinorelbine - Jul 27, 2005 Novacea and Pierre Fabre Medicament are to collaborate in the development and commercialization of oral vinorelbine, a chemotherapeutic agent, ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones … Pierre Fabre Medicament SA to develop oral vinorelbine for the... - Oct 1, 2005 Novacea partnered with Pierre Fabre Medicament SA to develop oral vinorelbine for the treatment of different types of tumors. ... $9.94 - Pharmaceutical Executive - Alacra Store Novacea Drops Vinorelbine To Focus On Other Cancer Drugs. - Nov 2, 2006 Novacea Inc. is shaking up its pipeline by abandoning oral vinorelbine (OV) in the face of higher-than-expected development costs, and it will instead focus ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Novacea Raises Over $25 Million in Private Financing. - Jan 4, 2006 The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase ... Free with registration - PR Newswire - AccessMyLibrary.com ERBITUX® Supplemental Biologics License Application for Advanced … - Dec 8, 2008 For patients receiving ERBITUX in combination with cisplatin/vinorelbine, median overall survival was prolonged by 1.2 months when compared to ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: ADVENTRX Appoints Vice President of … - Oct 8, 2007 About ANX-530 (vinorelbine emulsion). ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ... Pay-Per-View - PR Newswire - HighBeam Research Cancer Therapy; Findings describe new data in cancer therapy research - Dec 20, 2005 Study 1: Pemetrexed and vinorelbine could be used as a first-line treatment of ... "Pemetrexed and vinorelbine are active antineoplastic agents in NSCLC. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Novacea and Pierre Fabre Medicament Enter Into … - Jul 25, 2005 Oral vinorelbine provides a perfect fit for the Novacea model to in-license, ... With approximately 1000000 patients treated with vinorelbine, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: ADVENTRX Announces ANX-530 Safety Data From … - May 16, 2008 The abstract, entitled "Tolerability and incidence of infusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: XYOTAX(TM) Significantly Prolongs Survival in Poor … - May 15, 2005 Vinorelbine is the only single agent approved in the United States for treating first-line lung cancer. On study deaths were also significantly reduced ... Pay-Per-View - PR Newswire Europe - HighBeam Research Cancer Therapy; Recent findings in cancer therapy provide new insights - Mar 7, 2006 Study 2: Induction chemotherapy with gemcitabine and vinorelbine followed by ... Study 3: Vinorelbine plus gemcitabine was evaluated as third-line ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: XYOTAX(TM) Significantly Prolongs Survival in Poor … - May 15, 2005 Vinorelbine is the only single agent approved in the United States for treating first-line lung cancer. On study deaths were also significantly reduced ... Pay-Per-View - PR Newswire - HighBeam Research Does palliative chemotherapy beyond three courses benefit patients... - Jan 4, 2007 To compare the use of three versus six cycles of a platinum-based two-drug combination regimen (carboplatin and vinorelbine) in terms of QoL and survival ... Nature.com ADVENTRX Announces Positive FDA Pre-IND Meeting Outcome - Dec 7, 2005 ANX-530 is a novel, emulsion formulation of vinorelbine tartrate. Vinorelbine is a chemotherapeutic agent indicated as a single agent or in combination with ... RedOrbit Breast Cancer; Findings from Greece, the United Kingdom and Tokyo in ... - May 3, 2006 The combination of vinorelbine and gemcitabine is an active scheme in pretreated MBC, ... With the objective of determining the usefulness of vinorelbine ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones ADVENTRX Announces ANX-530 Safety Data and Provides NDA … - Jan 14, 2008 ANX-530 is a novel emulsion formulation of vinorelbine. Vinorelbine, marketed under the brand name Navelbine and available in generic versions, ... Free with registration - PR Newswire - AccessMyLibrary.com Cancer Therapy; Partnership formed to develop and commercialize new … - Aug 23, 2005 Pierre Fabre has licensed the US and Canadian rights to Novacea, while Pierre Fabre will continue to develop and commercialize oral vinorelbine in Europe ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones … added to cisplatin for advanced non-small-cell lung cancer—vinorelb... - Feb 8, 2005 ...(2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in ... Nature.com INX Inc intends a stock buyback - Deal Snapshot - AlacraStore.com - Dec 5, 2007 Its preclinical stage products include INX-#### (sphingosomal vinorelbine) and INX-#### (sphingosomal to potecan) for…Condition Treated Trial Phase ... Pay-Per-View - deals - Alacra Store ADVENTRX Acquires Additional Oncology Drug Through Exclusive … - Oct 4, 2005 Severe phlebitis is a known complication of standard vinorelbine therapy. Vinorelbine is currently used as a monotherapy or in combination with other ... $4.95 - Business Wire - ECNext Press Release: ADVENTRX Presents Positive ANX-530 Preclinical … - Apr 5, 2006 The presentation, entitled "A novel emulsion formulation of vinorelbine attenuates ... About ANX-530 (vinorelbine emulsion) ANX-530 is a novel emulsion ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Complete ANX-530 Safety Data to be Published in the … - Mar 10, 2008 ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to ... Pay-Per-View - PR Newswire - HighBeam Research ADVENTRX Appoints Vice President of Commercialization - Oct 8, 2007 ANX-530 is a novel emulsion formulation of vinorelbine tartrate, ... Vinorelbine tartrate works by disrupting microtubule formation and is a member of the ... Genetic Engineering News - Genetic Engineering News (press release) Hana Biosciences Initiates Phase I Clinical Trial of a Targeted … - Aug 3, 2006 This Phase I study is designed to assess the safety, tolerability and preliminary efficacy of Sphingosome Encapsulated Vinorelbine in patients with advanced ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: ADVENTRX to Present Complete ANX-530 … - Feb 7, 2008 The poster presentation entitled "Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in ... Pay-Per-View - PR Newswire - HighBeam Research Region Hovedstaden afventer redegørelse - Sep 24, 2008 Lægerne har i stedet givet behandling med stoffet Vinorelbine som led i et forsøg, der kører pÃ¥ Rigshospitalet. Der er angiveligt ikke lægelig dokumentation ... Fyens Stiftstidende DR: Rigshospitalet tav om kræftbehandling - Sep 24, 2008 Lægerne har i stedet givet behandling med stoffet Vinorelbine, som ifølge udsendelsen er forsøgsmedicin, hvis virkning ikke er dokumenteret. ... Berlingske Tidende - Berlingske Tidende (abonnement) … Therapeutics, Inc. (CTIC)'s OPAXIO(TM) With Gemcitabine or Vinorelb... - Jul 7, 2008 Vinorelbine was administered on days 1, 8, and 15 of each 21-day cycle. Patients received up to six cycles of treatment, and were not treated until ... Lifescience-online INX Inc intends a stock buyback - Deal Snapshot - AlacraStore.com - May 5, 2008 Its preclinical stage products include INX-#### (sphingosomal vinorelbine) and INX-#### (sphingosomal to potecan) for…Condition Treated Trial Phase ... Pay-Per-View - deals - Alacra Store Mesothelioma and Active Symptom Control - Jun 30, 2008 However, one chemotherapy drug—vinorelbine—is promising enough to warrant further study, ... Patients taking ASC plus vinorelbine lived, on average, ... Surviving Mesothelioma Mesothelioma and Chemo Results - Jun 17, 2008 Vinorelbine is already being used as part of first-line treatment for mesothelioma ... Patients received a weekly dose of up to 60 mg of vinorelbine through ... Surviving Mesothelioma ADVENTRX Announces Upcoming Scientific Conference Presentations. - Mar 28, 2006 ADVENTRX will present "A novel emulsion formulation of vinorelbine ... ANX-530 is a new formulation of vinorelbine tartrate that emulsifies the drug into a ... Free with registration - PR Newswire - AccessMyLibrary.com Failure of the addition of methylprednisolone to intermediate-dose … - May 28, 2007 Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and ... Nature.com Vinflunine – an active chemotherapy for treatment of advanced non... - Jan 30, 2006 Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson LL (2000) Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. ... Nature.com »Jeg blev manipuleret af Danmarks Radio« - Oct 3, 2008 I dokumentaren pÃ¥stÃ¥s det, at Jens Benn Sørensen har givet forsøgsmedicin til patienterne for egen vindings skyld ved at give Vinorelbine. ... Dagens Medicin Press Release: ADVENTRX Announces Positive FDA Pre-IND Meeting … - Dec 7, 2005 ANX-530 is a novel, emulsion formulation of vinorelbine tartrate. Vinorelbine is a chemotherapeutic agent indicated as a single agent or in combination with ... Pay-Per-View - PR Newswire - HighBeam Research Chemotherapy; Hana initiates phase I trial of a targeted chemotherapy... - Aug 29, 2006 Vinorelbine, a semisynthetic vinca alkaloid, is a microtubule inhibitor that has ... Vinorelbine is also widely used for the treatment of breast cancer. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones INX Inc intends a stock buyback - Deal Snapshot - AlacraStore.com - Sep 10, 2008 Its preclinical stage products include INX-#### (sphingosomal vinorelbine) and INX-#### (sphingosomal to potecan) for…Condition Treated Trial Phase ... Pay-Per-View - deals - Alacra Store Brand Names/Synonyms: Vinorelbine is also known by the following brand names and/or synonymsKW 2307; Kw 2307 Base; Navelbine; Navelbine Base; VINORELBINE; Vinorelbin; Vinorelbina [Spanish]; Vinorelbine Bitartrate; Vinorelbine Ditartarate; Vinorelbine Ditartrate; Vinorelbine Tartrate; Vinorelbinum [Latin] Drug Category: Vinorelbine is categorized under the following by the FDA: Radiation-Sensitizing Agents; Antineoplastic Agents; ATC:L01CA04 Dosage Forms: SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |